Advanced Biomed Inc. Common Stock (ADVB) - Total Assets
Based on the latest financial reports, Advanced Biomed Inc. Common Stock (ADVB) holds total assets worth $10.65 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Advanced Biomed Inc. Common Stock - Total Assets Trend (2021–2025)
This chart illustrates how Advanced Biomed Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see Advanced Biomed Inc. Common Stock market cap and net worth for the company's overall valuation and market capitalisation.
Advanced Biomed Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (June 2025)
Advanced Biomed Inc. Common Stock's total assets of $10.65 Million consist of 92.6% current assets and 7.4% non-current assets. Review Advanced Biomed Inc. Common Stock (ADVB) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.6% |
| Accounts Receivable | $7.96K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Advanced Biomed Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Advanced Biomed Inc. Common Stock (ADVB) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Advanced Biomed Inc. Common Stock's current assets represent 92.6% of total assets in 2025, an increase from 90.8% in 2021.
- Cash Position: Cash and equivalents constituted 44.6% of total assets in 2025, up from 6.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Advanced Biomed Inc. Common Stock Competitors by Total Assets
Key competitors of Advanced Biomed Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GeneDx Holdings Corp.
NASDAQ:WGS
|
USA | $481.49 Million |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Microba Life Sciences Ltd
AU:MAP
|
Australia | AU$43.35 Million |
|
Genetic Signatures Ltd
AU:GSS
|
Australia | AU$49.04 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
Advanced Biomed Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.38 | 1.88 | 1.67 |
| Quick Ratio | 7.38 | 1.88 | 1.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.10 Million | $3.62 Million | $2.02 Million |
Advanced Biomed Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Advanced Biomed Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.14 |
| Latest Market Cap to Assets Ratio | 1.62 |
| Asset Growth Rate (YoY) | 46.0% |
| Total Assets | $6.51 Million |
| Market Capitalization | $10.52 Million USD |
Valuation Analysis
Above Book Valuation: The market values Advanced Biomed Inc. Common Stock's assets above their book value (1.62x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Advanced Biomed Inc. Common Stock's assets grew by 46.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Advanced Biomed Inc. Common Stock (2021–2025)
The table below shows the annual total assets of Advanced Biomed Inc. Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $6.51 Million | +46.01% |
| 2024-06-30 | $4.46 Million | -3.04% |
| 2023-06-30 | $4.60 Million | -31.48% |
| 2022-06-30 | $6.71 Million | +567.10% |
| 2021-06-30 | $1.01 Million | -- |
About Advanced Biomed Inc. Common Stock
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagul… Read more